Real-world Persistence on Selexipag for Pulmonary Arterial Hypertension in Canada
Background: Safety and tolerability of selexipag in pulmonary arterial hypertension (PAH) was demonstrated in a phase 3 clinical trial. In this trial, up to 14% of patients receiving selexipag over a median period of 70 weeks prematurely discontinued therapy due to adverse events. However, no data a...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Elsevier
2026-02-01
|
| Collection: | CJC Open |
| Sujets: | |
| Accès en ligne: | http://www.sciencedirect.com/science/article/pii/S2589790X2500647X |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|